Thus, therapies that jointly target leptin signaling alongside anti-VEGF therapy may help breast cancer patients – many (but not all) of whom are obese – in which conventional anti-VEGF combination therapy is less effective, such as in Her2-negative breast cancer. Here, ERBB2 is linked to breast cancer.